Home
Drugs
Ranibizumab
Clinical Trials

Clinical Trials Related to Ranibizumab

Related studies linked through entity extraction aliases.

Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting

Status: RECRUITING
Phase: NA

A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2/PHASE3

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Status: RECRUITING
Phase: PHASE3

A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

Status: COMPLETED
Phase: PHASE1

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2/PHASE3

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)

Status: COMPLETED
Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

Status: UNKNOWN
Phase: PHASE3

Ranibizumab Versus Aflibercept for CRVO in Young Patients.

Status: UNKNOWN
Phase: PHASE4

Anti-VEGF in Real-world

Status: UNKNOWN
Phase: N/A

A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

Status: COMPLETED
Phase: PHASE2

A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

Status: COMPLETED
Phase: PHASE2

A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

Status: WITHDRAWN
Phase: PHASE3

601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

Status: UNKNOWN
Phase: PHASE2

A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

Status: COMPLETED
Phase: PHASE3

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections

Status: COMPLETED
Phase: N/A

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema

Status: UNKNOWN
Phase: PHASE4